Arcus Biosciences (NYSE: RCUS) is scheduled to announce its fourth-quarter earnings for the fiscal year 2025 before the market opens on February 24, 2026. Analysts anticipate that the company will report a loss of $0.97 per share for the quarter. Investors can access the earnings summary on the company’s website, which will provide details on the earnings call taking place on February 25, 2026, at 16:30 ET.
Stock Performance and Insider Trading Activity
As of the last trading session, shares of Arcus Biosciences opened at $18.87. The stock has a market capitalization of $2.04 billion and exhibits a price-to-earnings ratio of -5.48. The 50-day moving average stands at $22.20, while the 200-day moving average is $17.92. Over the past year, the stock has fluctuated between a low of $6.50 and a high of $26.40.
In recent insider trading activity, Carolyn C. Tang, the General Counsel, sold 7,658 shares on December 16 at an average price of $21.88, totaling approximately $167,557. Post-sale, Tang holds 131,544 shares valued at about $2,878,182.72, reflecting a decrease of 5.50% in her position. Additionally, Terry J. Rosen, Chief Executive Officer, divested 28,947 shares on the same day for around $633,360. Following this transaction, Rosen retains 2,220,553 shares valued at approximately $48,585,699.64, representing a 1.29% reduction in ownership.
Over the past three months, insiders have sold a total of 265,887 shares, amounting to $6,075,020, which represents 9.60% of the company’s stock currently owned by corporate insiders.
Analyst Ratings and Future Projections
Equity research analysts have recently provided varied assessments of Arcus Biosciences. HC Wainwright upgraded their price target from $28.00 to $32.00 with a “buy” rating on December 12. Similarly, Goldman Sachs Group elevated its rating from “neutral” to “buy,” adjusting the price target from $16.00 to $28.00 on January 12. Conversely, Weiss Ratings maintained a “sell (d-)” rating in a note dated January 21, while Bank of America raised its price objective from $17.00 to $26.00 with a “neutral” rating on November 28.
Overall, seven analysts currently rate the stock as a Buy, three recommend holding, and one suggests selling. According to data from MarketBeat, Arcus Biosciences holds a consensus rating of “Moderate Buy” with an average price target of $29.33.
Arcus Biosciences is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative cancer immunotherapies. The firm centers its research on modulating tumor microenvironments and immune checkpoints via both small-molecule and antibody-based candidates. Key clinical projects include etrumadenant, an oral A2A adenosine receptor antagonist, and domvanalimab, an anti-TIGIT monoclonal antibody, both aimed at enhancing antitumor immune responses.
For those interested in keeping up with the latest developments, Arcus Biosciences offers a daily email newsletter summarizing the latest news and analyst ratings.
